CAREY STEPHEN P.

CFO Carey Stephen P. sold 7,312 shares at $75.50 avg on 2026-03-05 for $552,031.04

Carey Stephen P., SVP & CFO of ANI Pharmaceuticals Inc, sold 7,312 shares via 2 separate transactions on 2026-03-05, realizing $552,031.04 at a blended average price of $75.50, reducing holdings from 192.9K to 185.5K shares (-3.8%). The stock currently trades at $75.60, down 5.4% over 30 days and 7.6% over 90 days, having declined 23.5% from its 52-week high of $98.81. At the same ticker (ANIP), the insider's prior 3 sales showed mixed timing outcomes: the most recent sale on 2025-08-12 was poorly timed (the stock gained 14.7% in the subsequent 30 days and 3.3% over 90 days), while only 1 of the 3 prior ANIP sales was well-timed at the 90-day mark. The company maintains solid fundamentals—43.8% annual revenue growth, $227.8M quarterly revenue, $26.6M net income, P/E of 13.43, and $1.8B market cap—providing no obvious fundamental distress signal accompanying this divestiture.

ANIP CFO Carey Stephen P. sold 50,000 shares at $86.07; stock now at $90.00; prior timing pattern mixed (50% well-timed rate).

CFO Carey Stephen P. sold 50,000 shares (180.9K post-transaction holdings, down 21.7%) at $86.07 on 2025-08-12, with the stock now trading at the 52-week high of $90.00 (+0.0% from peak). The timing context is nuanced: across his cross-ticker track record, his prior 2 sells showed an average 90-day return of -6.6% with a 50.00% well-timed rate (1 of 2 prior sells were well-timed at the 90-day mark), but at ANIP specifically, his 2 prior sales on 2024-03-11 and 2023-08-14 yielded mixed 90-day returns of +1.8% and -15.0% respectively (50% well-timed at this ticker). The fundamental backdrop shows revenue of $211,371,000.00 (quarterly), +26.2% annual growth, but the company was unprofitable over its most recent full fiscal year, suggesting profitability challenges despite revenue momentum. The sale occurs after a significant 30-day rally of +40.6% and 90-day surge of +50.0%, positioning the insider's execution at or near the recent valuation peak.